Health Care·Pharmaceuticals·$11.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | -281.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | -281.82% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions but remains focused on future growth. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite short-term setbacks.
Dr Reddy's Labs reported a loss per share of $0.60, which was below expectations. Despite this, the stock rose by 10.54%, likely due to investor optimism about long-term strategies discussed in the earnings call. The lack of revenue data and guidance may leave some investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TOPBUILD CORP
May 15, 2009